Finch Therapeutics Group, Inc. (FNCH)
USD 12.74
(-0.08%)
USD 12.74
(-0.08%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 28.4 Million USD | -41.93% |
| 2022 | 48.9 Million USD | 900.78% |
| 2021 | 4.88 Million USD | 170.3% |
| 2020 | 1.8 Million USD | -98.74% |
| 2019 | 143.66 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 27.55 Million USD | -100.0% |
| 2024 Q2 | 26.89 Million USD | 0.0% |
| 2023 Q1 | 32.88 Million USD | -32.77% |
| 2023 FY | 28.4 Million USD | -41.93% |
| 2023 Q4 | 28.4 Million USD | -1.38% |
| 2023 Q3 | 28.8 Million USD | -2.0% |
| 2023 Q2 | 29.38 Million USD | -10.63% |
| 2022 Q2 | 50.48 Million USD | 998.93% |
| 2022 FY | 48.9 Million USD | 900.78% |
| 2022 Q1 | 4.59 Million USD | -6.0% |
| 2022 Q4 | 48.9 Million USD | -1.61% |
| 2022 Q3 | 49.7 Million USD | -1.54% |
| 2021 Q1 | 1.8 Million USD | 0.0% |
| 2021 FY | 4.88 Million USD | 170.3% |
| 2021 Q4 | 4.88 Million USD | 0.0% |
| 2021 Q3 | - USD | -100.0% |
| 2021 Q2 | 724 Thousand USD | -59.96% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q4 | 1.8 Million USD | 0.0% |
| 2020 FY | 1.8 Million USD | -98.74% |
| 2019 FY | 143.66 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| America Great Health | 1.12 Million USD | -2428.897% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | 1.29 Million USD | -2098.375% |
| Biora Therapeutics, Inc. | 43.73 Million USD | 35.058% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -283930.0% |
| Better Therapeutics, Inc. | 10.34 Million USD | -174.478% |
| Calithera Biosciences, Inc. | 136 Thousand USD | -20784.559% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | -23509.749% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | -226.772% |
| Evelo Biosciences, Inc. | 48.87 Million USD | 41.891% |
| Evolutionary Genomics, Inc. | 3.74 Million USD | -658.678% |
| Galera Therapeutics, Inc. | 151.04 Million USD | 81.196% |
| Innovation1 Biotech Inc. | 218.99 Thousand USD | -12869.466% |
| Kiromic BioPharma, Inc. | 911.5 Thousand USD | -3016.072% |
| Molecular Templates, Inc. | 9.74 Million USD | -191.552% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | -1417.485% |
| NexImmune, Inc. | - USD | -Infinity% |
| Orgenesis Inc. | 19.06 Million USD | -48.964% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | -577.229% |
| Point of Care Nano-Technology, Inc. | - USD | -Infinity% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 104.33 Million USD | 72.778% |
| Statera Biopharma, Inc. | 11.43 Million USD | -148.47% |
| TRACON Pharmaceuticals, Inc. | 732 Thousand USD | -3780.191% |
| Trevena, Inc. | 35.23 Million USD | 19.385% |
| Vaxxinity, Inc. | 13.26 Million USD | -114.168% |
| Vaccinex, Inc. | 26 Thousand USD | -109142.308% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |